Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a negative opinion on Omeros’ marketing authorization application for narsoplimab, sold as Yartemlea in the United States, the company said on Friday. H.C. Wainwright views the weakness following the morning’s negative Committee for Medicinal Products for Human Use opinion as … Read more

Uber’s A ‘Compelling Investment Opportunity,’ Says Guggenheim – Flags Valuation Discount Versus Revenue, Profit Growth

Guggenheim reiterated its ‘Buy’ rating and $125 price target on Uber, with analyst Taylor Manley highlighting its growth profile and discount to the broader market. Manley argued that few internet companies of Uber’s scale are growing their top line by about 20% and profit by about 40% while trading at a discount to the market, … Read more

XOM Stock Climbs On $4.5B Refining Lift Estimate; Goldman Sees Q3 EPS Exceeding Wall Street Expectations

Margin improvement is expected to come mainly from a $4.5 billion rise in the refining and fuels business, the company said in a filing. The company said it saw no volume losses tied to Middle East events in the third quarter. Goldman Sachs analyst Neil Mehta said the filing implied Q3 earnings per share near … Read more

Delhi traders urge PM Modi, others to halt protests till Jan 2027

Delhi’s traders’ body, BUVM, has appealed to PM Modi, Rahul Gandhi, and Arvind Kejriwal to postpone all political protests in the capital until January 31, 2027, citing massive business losses during the crucial festival and wedding season. Amid the ongoing protests in the national capital, the Bharatiya Udyog Vyapar Mandal (BUVM), Delhi Pradesh, has written … Read more